Lifebloom promises to give people in wheelchairs the ability to walk on their own. Last week, the French MedTech company unveiled its Lifebloom One therapy. It includes an innovative medical device combining a wheelchair with an exoskeleton.
This is a major innovation that could change the lives of millions of people in wheelchairs. The French company Lifebloom, founded in 2019, has developed a new therapy to allow wheelchair users to stand and walk with more autonomy.
It took six years of research and an investment of 3 million euros to achieve this breakthrough. Damien Roche, founder of Lifebloom, said in a statement:
“In the world, 132 million people cannot walk on their own, even with the help of a walker. Being placed in a wheelchair is then the standard of care, but it’s also one of the greatest inefficiencies of our healthcare systems, degrading quality of life, increasing dependency, harming health, limiting rehabilitation, and overburdening caregivers. Since 2019, I’ve been driven by the belief that the ability to walk on your own and live standing should be accessible to everyone, regardless of age or disability. I’m proud today to unveil the Lifebloom One therapy, an alternative to a life confined to a seated wheelchair, preserving the ability to live standing.”


This therapy can be prescribed to most wheelchair users. Lifebloom One is available to people with reduced mobility due to:
- accidents (stroke, traumatic brain injuries, spinal cord injuries),
- illnesses (multiple sclerosis, Parkinson’s, Guillain-Barré syndrome),
- or deconditioning (frail elderly people) who retain at least partial lower limb mobility.
According to the MedTech company, 10.4 million people could benefit from this innovation every day and regain the ability to walk independently. But how exactly does it work?
RELATED ARTICLE
The Lifebloom One Therapy
Exoskeleton
Lifebloom One therapy includes various technologies. It starts with Oxilio, a medical device that combines an exoskeleton and a wheelchair. This device provides up to 80% anti-gravity assistance, lower limb oscillation assistance, balance support, and the reproduction of a natural gait. More compact and agile than a traditional wheelchair, this device can be used both in healthcare facilities and at home.
Digital Platform
The therapy also includes embedded systems for autonomous activity and gait analysis, along with a digital platform. This platform provides each user with dedicated content to enhance rehabilitation and self-rehabilitation. The idea is to unlock 100% of the patient’s recovery potential.
The reproduction of a natural walk, coupled with spending more time standing and walking, results in a therapeutic dose effect. The more one practices, the more one regains automatic walking, as well as strength and balance.
To motivate the patient to actively engage in their rehabilitation, the therapy includes daily achievable goals. Since rehabilitation is no longer limited to the therapy room, Lifebloom One provides caregivers with daily activity updates through a dedicated interface.

Preliminary Results and Therapy Deployment
As for results, according to the company, preliminary clinical efficacy tests conducted at the APHP Pitié-Salpêtrière Hospital by Prof. Eléonore Bayen on post-stroke patients unable to walk alone are encouraging. All regained independent walking and standing ability after starting the therapy, increasing their daily standing time by 596%.
Individuals can test the technology at Lille University Hospital. To make its solution available to the public as quickly as possible, Lifebloom plans to equip healthcare facilities (hospitals and rehabilitation centers) with dedicated care units called “Walking Units.”
Lifebloom has been recognized by several institutions such as the French Society of Rehabilitation and the American Academy of Medicine. The company also has a 5-million-euro development plan and is supported by the EU and France 2030.